The Safety of Driving Lp(a) Ultra-Low: Clear Skies with a Single Metabolic Cloud

Summary

In more than 25,000 patients with established atherosclerosis, ultra-low lipoprotein(a) levels carried no heightened risk of major bleeding, hemorrhagic stroke, cancer, cognitive decline, or atrial fibrillation. In contrast, a single safety signal persisted: lower Lp(a) concentrations were accompanied by an increased prevalence of diabetes. For the emerging wave of potent Lp(a)-silencing therapeutics approaching clinical practice, these findings paint a largely reassuring picture—with one specific metabolic nuance warranting vigilant surveillance.

Can Lipoprotein(a) Be ‘Too Low’?

Consider a 58-year-old female patient who has undergone placement of two stents in her left anterior descending artery. Supported by high-intensity statin therapy, her LDL cholesterol has finally fallen below target; however, her measured lipoprotein(a) level is 210 nmol/L. She inherited this trait from her father, who succumbed to a fatal myocardial infarction at just 61 years of age. Having read about investigational injectable agents capable of virtually eliminating this atherogenic particle, she asks an elemental question: Can this level be ‘too low’?

This concern is not unfounded. Arising relatively late in primate evolution, Lp(a) has long been hypothesized by clinicians to serve an adaptive biological purpose, such as wound healing and vascular repair. If so, near-total therapeutic ablation of this molecule might theoretically predispose patients to hemorrhagic events, tumorigenesis, or neurocognitive impairment. A secondary analysis from the FOURIER trial directly interrogates this concern.

The Study

Within the FOURIER trial, 27,564 patients with stable atherosclerotic cardiovascular disease, all receiving background statin therapy, were randomized to the PCSK9 inhibitor evolocumab or placebo^[1]. In this secondary analysis, investigators evaluated baseline Lp(a) levels in 25,090…